{"name":"Cellectar Biosciences","slug":"cellectar","ticker":"CLRB","exchange":"NASDAQ","domain":"cellectar.com","description":"Cellectar Biosciences is a clinical-stage biopharmaceutical company focused on the development of targeted phospholipid-drug conjugates (PDCs) for the treatment of cancer. The company's lead product, CLR 131, is a PDC that targets and selectively delivers cytotoxic radiation to cancer cells. Cellectar Biosciences has a strong pipeline of PDCs in various stages of development, with a focus on hematological malignancies and solid tumors.","hq":"Madison, WI","founded":0,"employees":"","ceo":"James Caruso","sector":"Oncology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":11498761,"netIncome":-21791037,"cash":13196033,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"CLR 131 patent cliff ($0.00 at risk)","drug":"CLR 131","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Iopofosine I 131 single dose","genericName":"Iopofosine I 131 single dose","slug":"iopofosine-i-131-single-dose","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Iopofosine I 131 multiple dose","genericName":"Iopofosine I 131 multiple dose","slug":"iopofosine-i-131-multiple-dose","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Iopofosine I 131 single dose","genericName":"Iopofosine I 131 single dose","slug":"iopofosine-i-131-single-dose","phase":"phase_2","mechanism":"Iopofosine I 131 is a phospholipid-drug conjugate that selectively targets and accumulates in cancer cells, allowing for targeted radiation therapy.","indications":["Relapsed or refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"Iopofosine I 131 multiple dose","genericName":"Iopofosine I 131 multiple dose","slug":"iopofosine-i-131-multiple-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Cellectar Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Cellectar Biosciences reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million and $54.1 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Cellectar Biosciences Announces $10 Million Registered Direct Offering","summary":"Cellectar Biosciences announced a registered direct offering of $10 million in gross proceeds to support its ongoing clinical trials.","drugName":"","sentiment":"neutral"},{"date":"2023-08-14","type":"trial","headline":"Cellectar Biosciences Announces Positive Interim Results from CLR 131 Phase 2 Clinical Trial","summary":"Cellectar Biosciences announced positive interim results from its CLR 131 Phase 2 clinical trial in patients with relapsed or refractory multiple myeloma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE05ajdrRmVrdERkQjVIOEFVWWJDdHlNdExILWNaXzFsSk1ZTmFZUTBURHRqT3B5eTZqbzE2bzJxNlhPaHh1dUM3cUoycUdSSGpsa0VVNmJ2N0gtV19iR0ROZ0tCV2pabWVkbkFIX1d3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Cellectar Biosciences Inc (CLRB) - Stock Titan","headline":"If You Invested $1,000 in Cellectar Biosciences Inc (CLRB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNUkxMa0lFTzNLV1cxZnpBMkEyZ1JnVG9iaEI5QVFyOGpyMEtvX2VXRXV3Q0JKM2o5VGpyM1ZoeGFPeExrU1ZxOVc2SktKTFRSNFREUGx6eVE2V1B1a0V6czZpZHZPNlJHOWxxYkc1bkdDMkZULVc0ZXlqTi0zbm9Nak1aV1BncWxXU1FYeWx6MTDSAZYBQVVfeXFMUG41Y04tRWZBVGZMYTFqaWhDTFh5RERMZEdwUFdRNWVVYWJJMWZIV2I2TVpKa1lXbEVySVhLd0gwOEVyLVVSaG1Cd3hBZzZtdWptdkExZjY0b0ZQaDVxNGVBeXBZU1dXNkZyeVZGUHZWT3pEVW9KWGtTa3IyX2Y4TnhjVDRNT3R0LUgtd1NEYmJWVlZ6MDVB?oc=5","date":"2026-03-06","type":"pipeline","source":"Cantech Letter","summary":"Should you sell your Cellectar Biosciences stock? - Cantech Letter","headline":"Should you sell your Cellectar Biosciences stock?","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOdUpxLW04YWc2VlQtTnh3UVpQcjdPRDJhUS11dGctY3dQSFRvd05nRE5Mc2l1c1c2ZWp0OUNZREt4eHZHYkRseVZCLTlOMXVzeGk1eW5GVzlTek5CdlllVEhKY1ppSl9HUmZHX1k1VzJINlByM19HdFBUNjlKN2FBNklGMWxRV0pZT1RLWmRNay1RY2JocG9zRXJWMnJQWVZqMFBmV25Pa0RjUEE1TUMtTWsyUzZhZGxTbW9MQUZxc2k?oc=5","date":"2026-02-25","type":"pipeline","source":"Stock Titan","summary":"Cancer-drug developer Cellectar sets March 4 call on 2025 results - Stock Titan","headline":"Cancer-drug developer Cellectar sets March 4 call on 2025 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNMFh5bEJiaXhRX0FQeGpSTnVJZlV5STRFWThHWTBja1VjNDFaRmZMTWZBVmpxZXVvMlUxb3F4RXNiejFqUm1uZ1BJdUFjWURRYk5WcEg2cFJkT0JjMmhjemtia2VURlBGa01QR0F5TzZ5by1ZejlrVEJjNWZYdHllclY3T0lOQUwzd3NaekpBc0RBcjNfN09QQWhKSVVWRkZQU1dWUjFUNnpTVWhfVlRoMWdIQQ?oc=5","date":"2026-02-17","type":"regulatory","source":"Stock Titan","summary":"New patents back Cellectar bid for EMA OK on Waldenström drug - Stock Titan","headline":"New patents back Cellectar bid for EMA OK on Waldenström drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPQ1JWYlkyVWRnX0JNOHQ4eTBIaVRFLTBaZEFPQ1J4b3Jld28ySGdqNk0zLUNkQnAyREZzNVVmd3d2eElQWkFQbHpvV2tqMG9CaXREZzl6NFV6TXhXSnNMZ29YTUo4dFJra2ktdk1uRnBuUFZGTVVDeDBObE9fWTJWN3pwNUp4bXR4Q3I1VzYyTG03bDJwT0FQZWdIUjU1dUZIcTBINnVtbHU5c3NNclBXX1dNbEZwdUNDN1YyTTc4YmdFR05pSmRtdlEyTUhUMlptZm9j?oc=5","date":"2026-01-12","type":"regulatory","source":"Benzinga","summary":"Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQU1hWZldGLUNjek9jTF9rb0o2QTctWW5xNk1Xc1hRM2pUc05MV2kwN0JJTGtGSnBSSm04MUFPaFptcW0tN0FHb3BFRjJQNnhfdkFWQmJMOHpBTGUydk9KdFBWN3RCdnczSjNXQ1VqbnlRZVFQZ0RpbzlyU2p6WkFXdW9JTUx0dUtTZFE1ZHdHdlFiT3dLMDBBY3lzYS1ZOXgwdXFnSzZmNlR6aElzOXI0?oc=5","date":"2025-02-02","type":"pipeline","source":"Investing.com","summary":"Cellectar faces Nasdaq delisting over share price rule - Investing.com","headline":"Cellectar faces Nasdaq delisting over share price rule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBZLXNrY0pIVzl0c3hYZ29Xd3pkMzJrZEVQdW9DcThjSU1aSGV2Z0dmdmlHUTIxZVhUTi13X09hVjVqZk5hTzJycVE0VXFqUG1R?oc=5","date":"2024-01-08","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"CLR 131","drugSlug":"iodine-131","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Novartis","Sanofi"],"therapeuticFocus":["Oncology","Hematology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11498761,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-21791037,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":13196033,"cashHistory":[],"totalAssets":14978321,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}